Linagliptin Sandoz (Linagliptin)

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prolongs the activity of incretin hormones GLP‑1 and GIP, which increase insulin secretion and decrease glucagon release in a glucose‑dependent manner, thereby lowering blood sugar without causing significant hypoglycaemia on its own.

The exact dosage of Linagliptin Sandoz is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for Linagliptin Sandoz during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and always under medical supervision.

To order Linagliptin Sandoz, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin is distinguished by its primarily non‑renal elimination, allowing use without dose adjustment in patients with renal impairment, unlike some other DPP‑4 inhibitors that require renal dosing. Its efficacy and safety profile are comparable to other agents in the class, but individual patient factors guide the choice of therapy.

Linagliptin Sandoz should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain its stability throughout its shelf life.

Linagliptin Sandoz is taken orally as a tablet, usually once daily. It can be swallowed with or without food, and patients should follow the dosing schedule prescribed by their healthcare provider for consistent blood‑glucose management.

The most serious risks include acute pancreatitis, severe allergic reactions such as anaphylaxis, and, when combined with insulin or sulfonylureas, potentially dangerous hypoglycaemia. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of low blood sugar.

Linagliptin Sandoz should not be used by individuals with a known hypersensitivity to linagliptin or any of its excipients. Caution is also advised for patients with a history of pancreatitis, severe hepatic impairment, or those taking medications that may cause significant drug‑drug interactions.